Navigation Links
TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
Date:8/27/2007

- Tezampanel Development Targeting Chronic Pain Conditions; Compound

Currently in Phase IIb Clinical Trial for Acute Migraine -

LA JOLLA, Calif., Aug. 27 /PRNewswire-FirstCall/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that it has initiated a Phase I multiple dose clinical trial to evaluate the safety, tolerability and pharmacokinetics of tezampanel given as a subcutaneous injection to healthy male and female volunteers once-daily for four consecutive days. Tezampanel, an AMPA/kainate (AK) receptor antagonist that selectively binds to certain AK receptors to potentially block the transmission of pain signals, has been administered in single doses to more than 300 patients and healthy adults. Data from this multiple dose trial will support the continued development of tezampanel for the treatment of migraine as well as allow TorreyPines to consider expanding the development of tezampanel into additional chronic pain conditions.

The double-blind, placebo-controlled, multiple-dose trial will be conducted at one center in the United States. Approximately 30 healthy male and female volunteers, between the ages of 21 and 55, will be enrolled in sequential, dose-escalating cohorts and receive once-daily subcutaneous doses of placebo or 40 mg, 70 mg or 100 mg of tezampanel for four consecutive days. These same dose strengths, given as a single dose subcutaneous injection, are currently being evaluated by TorreyPines in a Phase IIb clinical trial of tezampanel for acute migraine.

"We are pleased with our development progress for tezampanel," said Neil Kurtz, M.D., President and Chief Executive Officer of TorreyPines. "Our Phase IIb trial in migraine has completed enrollment
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014  BC Technical, the largest nationwide, non-OEM ... , Inc., a leading provider of Siemens Nuclear Medicine ... agreement naming BC Technical as the authorized provider of ... MiE and BC Technical announced today that the two ... Technical as the service and systems provider for MiE,s ...
(Date:7/10/2014)... , July 10, 2014   Ventana Medical Systems, ... announced it has entered into an agreement with Merck ... as EMD Serono in the United States ... collaborate with Merck KGaA,s biopharmaceutical division on the development ... undisclosed target using Ventana,s proprietary diagnostic assays. In alignment ...
(Date:7/10/2014)... 2014   LabStyle Innovations Corp . (OTCQB:DRIO), developer ... the appointment of Professor Richard B. Stone ... of Directors. Prof. Stone brings over ... LabStyle as an entrepreneur, venture capitalist public, company ... expert. He currently serves on the board of ...
Breaking Medicine Technology:BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4
... With obesity in America reaching alarming levels -- across our adult and youth ... who used BodyMedia,s wearable body-monitoring technology either in conjunction with a group weight loss ... three times more weight than individuals who attempted ... ...
... Ill., March 11 The U.S. Food ... supplemental new drug application (sNDA) of a new six-month ... Depot (leuprolide acetate for depot suspension) for ...  Palliative treatment helps to relieve symptoms associated with advanced ...
Cached Medicine Technology:The Results are in: Users of BodyMedia's Wearable Body-Monitoring Technology Lose 3 Times More Weight 2The Results are in: Users of BodyMedia's Wearable Body-Monitoring Technology Lose 3 Times More Weight 3The Results are in: Users of BodyMedia's Wearable Body-Monitoring Technology Lose 3 Times More Weight 4The Results are in: Users of BodyMedia's Wearable Body-Monitoring Technology Lose 3 Times More Weight 5The Results are in: Users of BodyMedia's Wearable Body-Monitoring Technology Lose 3 Times More Weight 6Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 2Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 3Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 4Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 5Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 6Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 7
(Date:7/12/2014)... 2014 The fastest-growing mobile technology is ... measurement of LTE networks continues to grow due to ... devices have increased mobile data traffic, which is a ... market. Communications Test and Measurement equipment comply with industry ... Communications Test and Measurement Market is estimated to grown ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 "The second toes ... uncomfortable and painful to wear shoes," said an inventor from ... sock that prevents this from happening. , He then created ... way to prevent the second and big toes from overlapping. ... while wearing shoes. Ergonomic and easy to use, it's ideal ...
(Date:7/12/2014)... prom shopping reaching its final days, VogueQueen.com, a renowned ... its new and trendy apparels. Recently, the company has ... online shop. Additionally, it is now providing huge discounts ... to the company’s sales manager, the promotion will come ... He says, “Now, worldwide clients can order cheap ...
(Date:7/12/2014)... As reported in this July 1st article ... the June 25th, 2014 Supreme Court ruling in Riley v ... It was also met with both cheers and jeers when ... seen from an individual privacy perspective, or a law enforcement ... now precedent which will require law enforcement officials to obtain ...
(Date:7/12/2014)... Wright & Schulte LLC, an experienced law firm ... Lawsuits (case #59776/2014), announces they have launched a new ... the popular hair dye, Just For Men, has caused some ... and other areas. In addition to detailing symptoms that are ... the advertisements being run by Wright & Schulte LLC will ...
Breaking Medicine News(10 mins):Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 5Health News:VogueQueen.com Updates Its Summer Collection With New And Trendy Evening Dresses 2Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 2Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 3Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 4Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 5Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 2Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 3Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 4
... halted early because of supplement,s poor performance , SATURDAY, ... supplement selenium doesn,t reduce the likelihood of lung cancer ... Daniel D. Karp, a professor in the department of ... Texas M.D. Anderson Cancer Center, is scheduled to present ...
... ... Dad,” and Faces iMake, among Father’s Day 2010 GreatDad Recommends Award and Mr. Dad Seal ... San ... Day activities this year are in for a real treat. Presented by Mr. Dad and ...
... ... and prisons , ... (PRWEB) June 5, 2010 -- President Narconon International, Clark Carr, just finished his fourth ... relapse prevention technology to Mexico. Accompanied by U.S. and Mexican volunteers, Carr demonstrated pain ...
... ... Savory, the Savory Institute and the Africa Centre for Holistic Management are winning awards for ... and rivers back to life, increase food production and security and store carbon in ever ... ...
... According to new research that will be presented on Saturday, ... Academy of Dental Sleep Medicine, the majority of U.S. dental ... sleep disorders, which affect more than 70 million adults in ... - Los Angeles (UCLA) School of Dentistry surveyed each of ...
... According to new research that will be presented on ... the American Academy of Dental Sleep Medicine, between 31 ... sleep apnea treatment remained effective. Subjective daytime sleepiness, fatigue ... Mandibular advancement appliances (MAA) have been shown to ...
Cached Medicine News:Health News:Don't Count on Selenium to Prevent Lung Cancer Recurrence 2Health News:Mr. Dad and GreatDad.com Salute Fathers and Families with This Spring's ‘Seal of Approval' Picks 2Health News:Mr. Dad and GreatDad.com Salute Fathers and Families with This Spring's ‘Seal of Approval' Picks 3Health News:Mr. Dad and GreatDad.com Salute Fathers and Families with This Spring's ‘Seal of Approval' Picks 4Health News:Narconon Campaigns to Help Mexico Reduce Drug-related Violence in Sonora and Michoacan 2Health News:Holistic Management and Allan Savory Win the 2010 Buckminster Fuller Award for Turning Deserts into Thriving Grasslands and Combating Climate Change. 2Health News:US dental schools leave graduates unprepared to screen for sleep disorders 2Health News:Sleep apnea patients using oral appliance therapy show high efficacy and compliance 2
... slot into the side ... monitor, so patient information ... patient's side. Data is ... and storage at the ...
... Telemetry System is a telemetry system ... which require monitoring and performance. With ... able to monitor patients from virtually ... and wireless bedsides. Now, monitoring your ...
TeleRehab Advantage is a monitoring system that automates the generation of outcomes data. Patient information and session information is automatically transferred from the monitoring program to Outc...
... Clearly, the ISI Lexan Universal ... surgical table for lower and ... head and neck, and lower ... traction package gives you the ...
Medicine Products: